Overview
Sponsor-declared trial summary
Refractory Focal Onset Epilepsy
To evaluate the safety and tolerability of BHV-7000
Key facts
- Sponsor
- Biohaven Therapeutics Ltd.
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Nervous System Diseases [C10]
- Trial duration
- 18 Dec 2024 → ongoing
- Decision date (initial)
- 2024-10-14
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
- Funding sources
- Biohaven Therapeutics, Ltd.
External identifiers
- EU CT number
- 2023-508813-18-00
- ClinicalTrials.gov
- NCT06443463
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Others, Efficacy, Safety
To evaluate the safety and tolerability of BHV-7000
Conditions and MedDRA coding
Refractory Focal Onset Epilepsy
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 21.1 | LLT | 10065337 | Focal epilepsy | 10029205 |
Study design 1 period
| # | Title | Allocation | Blinding | Roles blinded | Arms |
|---|---|---|---|---|---|
| 1 | Safety and tolerability of BHV-7000 assessment phase Eligible subjects who completed the DBP of the BHV7000-302 study will be initially assigned BHV-7000 50 mg dose at the baseline visit.
Eligible subjects who completed the DBP of the BHV7000-303 study will be initially assigned BHV-7000 75 mg dose at the baseline visit
|
2 | None | BHV-7000 50mg: 50mg dose BHV-7000 75mg: 75mg dose |
Regulatory references
- Scientific advice from competent authorities
- European Medicines Agency, Food And Drug Administration
- Plan to share IPD
- No
| EU CT number | Title | Sponsor |
|---|---|---|
| 2023-508811-21-00 | A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy | Biohaven Therapeutics Ltd. |
| 2023-508812-45-00 | A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension | Biohaven Therapeutics Ltd. |
| 2023-508539-30-00 | A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy | Biohaven Therapeutics Ltd. |
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 2
- 1. Subjects who completed the double-blind phase (DBP) of prior parent study, BHV7000-302 or BHV7000-303.
- 2. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at the Baseline/Day 0 visit.
Exclusion criteria 2
- 1. Any condition, such as an ongoing AE with/without sequalae, or is poorly tolerating IP in the DBP of the parent study, that would interfere with the subject’s ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator.
- 2. Any medical condition, based on the judgement of the Investigator, that would confound the ability to adequately assess safety and efficacy outcome measures.
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 1
- Safety is assessed by the number of unique subjects with deaths, SAE’s, AE’s leading to discontinuation, moderate and severe AEs and grade 3 and 4 laboratory abnormalities
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 2
PRD10918476 · Product
- Active substance
- BHV-7000
- Pharmaceutical form
- PROLONGED-RELEASE TABLET
- Route of administration
- ORAL
- Max daily dose
- 75 mg milligram(s)
- Max total dose
- 27300 mg milligram(s)
- Max treatment duration
- 52 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- BIOHAVEN THERAPEUTICS LTD
- Paediatric formulation
- No
- Orphan designation
- No
PRD10918475 · Product
- Active substance
- BHV-7000
- Pharmaceutical form
- PROLONGED-RELEASE TABLET
- Route of administration
- ORAL
- Max daily dose
- 75 mg milligram(s)
- Max total dose
- 27300 mg milligram(s)
- Max treatment duration
- 52 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- BIOHAVEN THERAPEUTICS LTD
- Paediatric formulation
- No
- Orphan designation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Biohaven Therapeutics Ltd.
- Sponsor organisation
- Biohaven Therapeutics Ltd.
- Address
- 215 Church Street
- City
- New Haven
- Postcode
- 06510-1803
- Country
- United States
Scientific contact point
- Organisation
- Biohaven Therapeutics Ltd.
- Contact name
- Research and Development Medical Director
Public contact point
- Organisation
- Biohaven Therapeutics Ltd.
- Contact name
- Chief Operating Officer
Third parties 8
| Organisation | City, country | Duties |
|---|---|---|
| Medidata Solutions Inc. ORG-100016256
|
New York, United States | E-data capture |
| 4g Clinical LLC ORG-100042775
|
Wellesley, United States | Interactive response technologies (IRT) |
| PPD Global Ltd. ORG-100007531
|
Marousi, Greece | On site monitoring, Code 5 |
| PPD Global Central Labs ORG-100046496
|
Zaventem, Belgium | Laboratory analysis |
| Eresearchtechnology Inc. ORG-100013039
|
Philadelphia, United States | Other |
| PPD Development LP ORG-100011560
|
Wilmington, United States | On site monitoring, Code 11, Code 12, Code 13, Code 14, Code 2, Code 5, Data management, Code 8, Code 9 |
| WCG Clinical Inc. ORG-100040730
|
Plymouth Meeting, United States | Other |
| Scout Clinical ORG-100042228
|
Dallas, United States | Other |
Locations
18 EU/EEA countries · 117 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Ongoing, recruiting | 5 | 4 |
| Belgium | Ongoing, recruiting | 20 | 5 |
| Croatia | Authorised, recruiting | 20 | 4 |
| Czechia | Ongoing, recruiting | 18 | 2 |
| Denmark | Ongoing, recruiting | 28 | 3 |
| Finland | Ongoing, recruiting | 8 | 3 |
| France | Ongoing, recruiting | 24 | 9 |
| Germany | Ongoing, recruiting | 54 | 14 |
| Greece | Ongoing, recruiting | 18 | 6 |
| Hungary | Ongoing, recruiting | 20 | 4 |
| Italy | Ongoing, recruiting | 48 | 17 |
| Netherlands | Ongoing, recruiting | 8 | 3 |
| Poland | Ongoing, recruiting | 82 | 15 |
| Portugal | Ongoing, recruiting | 18 | 6 |
| Romania | Ongoing, recruiting | 12 | 2 |
| Slovakia | Ongoing, recruiting | 6 | 2 |
| Slovenia | Ongoing, recruiting | 8 | 1 |
| Spain | Ongoing, recruiting | 51 | 17 |
| Rest of world
Chile, United Kingdom, United States, South Africa, Switzerland, Argentina, Mexico, Australia
|
— | 279 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Austria | 2025-04-24 | 2025-07-02 | |||
| Belgium | 2025-03-28 | 2025-04-24 | |||
| Croatia | 2025-07-02 | ||||
| Czechia | 2025-05-21 | 2025-06-17 | |||
| Denmark | 2025-02-18 | 2025-04-02 | |||
| Finland | 2025-06-16 | 2025-07-31 | |||
| France | 2025-06-11 | 2025-08-26 | |||
| Germany | 2025-04-29 | 2025-05-26 | |||
| Greece | 2025-09-03 | 2025-10-08 | |||
| Hungary | 2025-02-10 | 2025-03-25 | |||
| Italy | 2025-03-28 | 2025-05-14 | |||
| Netherlands | 2025-08-21 | 2025-09-30 | |||
| Poland | 2025-02-04 | 2025-03-13 | |||
| Portugal | 2025-02-24 | 2025-07-01 | |||
| Romania | 2025-10-14 | 2025-11-19 | |||
| Slovakia | 2025-12-15 | 2026-01-14 | |||
| Slovenia | 2025-03-20 | 2025-04-21 | |||
| Spain | 2024-12-18 | 2025-03-06 |
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 178 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_Biohaven_BHV-7000-201_Protocol_2023-508813-18-00_GRC_Public | 1.3 |
| Protocol (for publication) | D1_Biohaven_BHV-7000-201_Protocol_2023-508813-18-00_Public | 1.3 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_AUT_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_CAT for ESP_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_CZE_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_DEU_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_ENG_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_ESP_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_FRA for BEL_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_FRA_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_GRC_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_HRV_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_HUN_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_ITA_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_NLD for BEL_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_POL_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_POR_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_ROU_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_SVK_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Dosing Diaries_SVN_Public | 2.0 |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_AUT_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_CZE_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_DEU_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_ENG_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_ESP_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_FRA for BEL_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_FRA_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_GRC_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_HRV_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_HUN_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_ITA_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_NLD for BEL_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_POL_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_PRT_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_ROU_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_SVK_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_Scales PFMs_SVN_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_AT_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_CZ_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_DE_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_EN_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_ES_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_FR for BE_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_FR_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_GR_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_HR_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_HU_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_IT_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_NL for BE_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_PL_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_PT_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_RO_Public | N/A |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_SI_Public | n/a |
| Protocol (for publication) | D4_Biohaven_BHV7000-201_WCG eDiary PFMs_SK_Public | N/A |
| Recruitment arrangements (for publication) | K1_BHV-7000-201_Recruitment Informed Consent Procedure_BE_Public | 2 |
| Recruitment arrangements (for publication) | K1_BHV-7000-201_Recruitment_Procedure_FRA_French_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV-7000-201_Recruitment-Arrangements_DNK_English_Public | 1.0 |
| Recruitment arrangements (for publication) | K1_BHV-7000-201_Recruitment-Informed-Consent-Procedure_HRV_English_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment and Informed consent procedure_CZE_English_Public | 1.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment arrangements_FIN_Finnish_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment_Arrangements_SLO_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment_Arrangements_SLO_TC_NotPublic | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment_Informed_Consent_Procedure_AT_Public | 1.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment_Informed_Consent_Procedure_HU_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangements_ES_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangements_GRC_English_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangements_IT_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangements_NL_English_Public | n/a |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangements_PL_Polish_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangements_PT_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangements_ROU_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangements_SK_Public | 2.0 |
| Recruitment arrangements (for publication) | K1_BHV7000-201_Recruitment-Arrangments_DE_Public | 2.0 |
| Recruitment arrangements (for publication) | K2_BHV7000-201_GP-Letter_IT_Italian_Public | 2.0 |
| Subject information and informed consent form (for publication) | L_BHV7000-201_List-of-submitted-patient-material_Public | n/a |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Caregiver_ICF_GRC_English_Public | 3.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Caregiver_ICF_GRC_Greek_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Caregiver-ICF_HRV_Croatian_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_GDPR-ICF_SK_Slovak_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_ICF_GDPR_CZE_Czech_Public | 3.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_ICF_Main_CZE_Czech_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_ICF_Pregnant Partner_CZE_Czech_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_ICF-Main_DNK_Danish_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_ICF-PP_DNK_Danish_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main ICF HUN Hungarian_Public | 4 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main ICF_FIN_Finnish_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main_ICF_ES_Spanish_Public | 3.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main_ICF_FRA_French_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main_ICF_IT_Italian_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_BE_Dutch_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_BE_English_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_BE_French_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_DE_German_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_ES_Catalan_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_GRC_English_Public | 3.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_GRC_Greek_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_HRV_Croatian_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_PL_Polish_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_PT_Portuguese_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_ROU_English_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_ROU_Romanian_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_SK_Slovak_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Main-ICF_SLO_Slovenian_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Optional-Use-Scout-Clinical-for-Caregiver_HRV_Croatian_Public | 1.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Optional-Use-Scout-Clinical-for-Subject_HRV_Croatian_Public | 1.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_PP ICF_FIN_Finnish_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_PP-ICF_AT_German_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_PP-ICF_PL_Polish_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnancy-and-Newborn-Data-Collection-ICF_PT_Portuguese_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnancy-FUP-and-Newborn-ICF_BE_Dutch_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnancy-FUP-and-Newborn-ICF_BE_English_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnancy-FUP-and-Newborn-ICF_BE_French_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnancy-Newborn_ICF_GRC_English_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnancy-Newborn_ICF_GRC_Greek_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant Partner ICF_HUN Hungarian_Public | 1.2 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant_Partner_Patient_ICF_FRA_French_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Participant-ICF_HRV_Croatian_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Partner_ICF_ES_Spanish_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Partner-and-Participant-ICF_DE_German_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Partner-ICF_ES_Catalan_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Partner-ICF_HRV_Croatian_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Partner-ICF_ROU_English_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Partner-ICF_ROU_Romanian_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Partner-ICF_SLO_Slovenian_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Partner-Participant-ICF_SK_Slovak_Public | 2.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_Pregnant-Subject-ICF_SLO_Slovenian_Public | 1.1 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_SIS-and-ICF_Adults_NL_Dutch_Public | 4.0 |
| Subject information and informed consent form (for publication) | L1_BHV7000-201_SIS-and-ICF_Pregnancy_NL_Dutch_Public | 1.1 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Concomitant Medication Diary Log_CZE_Czech_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Concomitant Medication Paper Diary_SK_Slovak_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Concomitant-Medication-Paper-Diary_HRV_Croatian_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Concomitant-Medication-Paper-Diary_PT_Portuguese_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_ConMed-Paper-Diary_SLO_Slovenian_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Country-Patient-Card_PT_Portuguese_Public | 1.0.2 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Email-Comm_PT_Portuguese_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Patient card_HU_Hungarian_Public | 1.0.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Patient_Card_CZE_Czech_Public | 1.0.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Patient_Card_FRA_French_Public | 1.0.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Patient-Card_HRV_Croatian_Public | 1.0.1 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_PregnacyReminderCard_HRV_Croatian_Public | 1.0.1 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Pregnancy-Reminder-Card_PT_Portuguese_Public | 3.0.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Pregnant_Partner_ICF_IT_Italian_Public | 3.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Reloadable-ScoutPass-Mailer_PT_Portuguese_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_SC_Email-Comm_HRV_Croatian_Public | 1 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_SC_Email-Comm_SLO_Slovenian_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_SC_PFD_Study-Brochure_HRV_Croatian_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_SC_PFD_Taxable-Payments-Letter_Template_HRV_Croatian_Public | 3.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_SC_Study-Brochure_SLO_Slovenian_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_SC_Taxable-Payments-Letter_SLO_Slovenian_Public | 3.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Scout Clinical_Email communication_CZE_Czech_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Scout Clinical_Study Brochure_CZE_Czech_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Scout Clinical_Taxable Payments Letter_CZE_Czech_Public | 3.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_ScoutPass-Reloadable_PT_Portuguese_Public | 1.0 |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Site-and-Patient-Advocacy-Contact-List-for-ICF_AT_Public | N/A |
| Subject information and informed consent form (for publication) | L2_BHV7000-201_Study-Brochure_PT_Portuguese_Public | 1.0 |
| Subject information and informed consent form (for publication) | L3_BHV7000-201_Con Med Paper Diary_HUN Hungarian_Public | 1.0 |
| Subject information and informed consent form (for publication) | L3_BHV7000-201_Patient-Card_SK_Slovak_Public | 1.1.1 |
| Subject information and informed consent form (for publication) | L3_BHV7000-201_Pregnacy-Reminder-Card_SK_Slovak_Public | 1.0.1 |
| Subject information and informed consent form (for publication) | L3_BHV7000-201_Privacy_Annex_1_ICF_IT_Italian_Public | 3.0 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_CZE_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_DEU for BEL_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_ESP_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_FRA for BEL_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_FRA_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_GRC_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_HRV_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_HUN_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_ITA_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_NLD for BEL_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_NLD_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_POL_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_PRT_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_ROU_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_SVK_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol lay language synopsis_2023-508813-18-00_SVN_Public | 1.3 |
| Synopsis of the protocol (for publication) | D1_Biohaven_BHV7000-201_Protocol synopsis_2023-508813-18-00_DEU for AUT_Public | 1.3 |
Application history
19 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-06-14 | Finland | Acceptable 2024-10-07
|
2024-10-07 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2024-10-31 | Acceptable 2024-10-07
|
2024-10-31 | |
| 3 | NON SUBSTANTIAL MODIFICATION | NSM-2 | 2024-11-06 | Acceptable 2024-10-07
|
2024-11-06 | |
| 4 | NON SUBSTANTIAL MODIFICATION | NSM-3 | 2024-11-12 | Acceptable 2024-10-07
|
2024-11-12 | |
| 5 | SUBSTANTIAL MODIFICATION | SM-1 | 2024-11-15 | Acceptable | 2025-01-14 | |
| 6 | SUBSTANTIAL MODIFICATION | SM-2 | 2024-11-15 | Acceptable | 2024-12-06 | |
| 7 | SUBSTANTIAL MODIFICATION | SM-3 | 2024-11-20 | Acceptable | 2025-01-16 | |
| 8 | SUBSTANTIAL MODIFICATION | SM-4 | 2024-11-22 | Acceptable | 2025-01-17 | |
| 9 | NON SUBSTANTIAL MODIFICATION | NSM-4 | 2025-01-21 | 2025-01-21 | ||
| 10 | SUBSTANTIAL MODIFICATION | SM-5 | 2025-04-07 | Acceptable | 2025-05-13 | |
| 11 | SUBSTANTIAL MODIFICATION | SM-6 | 2025-05-16 | Finland | Acceptable 2025-08-12
|
2025-08-12 |
| 12 | NON SUBSTANTIAL MODIFICATION | NSM-5 | 2025-09-12 | Finland | Acceptable 2025-08-12
|
2025-09-12 |
| 13 | SUBSTANTIAL MODIFICATION | SM-7 | 2025-10-16 | Finland | Acceptable with conditions 2026-02-02
|
2026-02-02 |
| 14 | SUBSTANTIAL MODIFICATION | SM-10 | 2026-02-11 | Acceptable with conditions | 2026-03-25 | |
| 15 | SUBSTANTIAL MODIFICATION | SM-8 | 2026-02-17 | Acceptable with conditions | 2026-03-23 | |
| 16 | SUBSTANTIAL MODIFICATION | SM-9 | 2026-02-23 | Acceptable with conditions | 2026-04-07 | |
| 17 | SUBSTANTIAL MODIFICATION | SM-11 | 2026-03-06 | Acceptable with conditions | 2026-03-18 | |
| 18 | SUBSTANTIAL MODIFICATION | SM-12 | 2026-04-21 | Acceptable with conditions | 2026-04-22 | |
| 19 | NON SUBSTANTIAL MODIFICATION | NSM-6 | 2026-05-21 | Acceptable with conditions | 2026-05-21 |